Latest News
-
Jan. 7, 2021
Gemini Therapeutics Announces FDA Fast Track Designation Granted for GEM103 for the Treatment of Dry Age-Related Macular Degeneration (AMD) in Patients with Complement Factor H (CFH) Loss of Function Gene Variants
-
Nov. 13, 2020
Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Study
-
Nov. 10, 2020
Gemini Therapeutics to Participate in Upcoming Investor Conferences